A new dimension of FDG-PET interpretation: assessment of tumor biology.
about
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's SyndromeEvidence based imaging strategies for solitary pulmonary nodule.Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.Correlation between histological grade and positron emission tomography parameters in cervical carcinoma.Imaging of solitary pulmonary nodule-a clinical reviewIn Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer 68Ga-NODAGA-Procainamide (PCA).Optical and opto-acoustic interventional imaging.Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity.Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.Nuclear medicine, scientific publishing and the era of cost containment: what factors hold the key?Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.Bottom up design of nanoparticles for anti-cancer diapeutics: "put the drug in the cancer's food".¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!
P2860
Q33669828-01341C4D-EB36-4B1E-A53D-C9004848A029Q33702522-3FE1BDED-DB37-4066-BBD6-AC98F9E77599Q33995254-5AE52C9A-E6DC-462D-8841-6CFEAE2D795CQ37063180-54FF4B7A-F540-4A3A-AD9D-C2E81A18DB56Q37106866-41E51B75-5A62-4997-A2A7-F90B923E88A5Q37441366-FFDA7A3D-F598-4308-93D0-C87E25EFEAF0Q37738077-CFF79648-C32E-43B3-9B89-D839A5639E11Q37974089-57D37E74-5D74-412B-971C-AB78C5A03000Q38123245-DA4724AB-ACC5-456F-90FB-12FA7F1F9744Q40715262-4F3640BB-61A4-4D8D-A688-238FC1A5D40AQ43803622-3605BC41-CB3F-456A-8A48-C5AFD81D2672Q44627038-8F16E1D4-B7C1-4656-866B-012B3F103332Q45111084-6CE5EB52-DD7E-4A2E-95D4-BC65BCB787E4Q50661596-06AF97A2-DF04-45D0-86B4-9495BEA045C5Q50878255-15F71BF8-CDB7-4065-A7E5-9AF0C91253D7Q51159201-BF8DB4D3-BC9D-4C14-B33A-3BF8F9B06D23Q53092282-B294A9CC-1689-4D62-B5C5-556A5412E9D7Q53108614-93ECEF0F-3B0F-45A9-B557-854EE2A26897Q54969527-06613F75-D15F-4D1B-A350-55591FCF58FF
P2860
A new dimension of FDG-PET interpretation: assessment of tumor biology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@en
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@nl
type
label
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@en
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@nl
prefLabel
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@en
A new dimension of FDG-PET interpretation: assessment of tumor biology.
@nl
P2093
P2860
P1476
A new dimension of FDG-PET interpretation: assessment of tumor biology
@en
P2093
Abass Alavi
Drew A Torigian
Sandip Basu
Thomas C Kwee
P2860
P2888
P304
P356
10.1007/S00259-010-1713-9
P577
2011-01-12T00:00:00Z